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Abstract
Cardiovascular disease, caused predominantly by atherosclerotic plaque rupture, remains one of the leading
causes of death. However, the mechanism of plaque rupture remains largely unknown. Recent studies have
linked high metabolic activity in inflamed atherosclerotic plaques to the development of plaque rupture.
AGEs (advanced glycation end-products) are known to be formed as a result of high metabolic activity
and are higher in rupture-prone than stable plaques. Furthermore, AGEs seem to be more than mere
markers of metabolic activity, as recent studies have elucidated that AGEs and their major precursor, MG
(methylglyoxal), may have an important role in the progression of atherosclerosis and plaque rupture. MG
can be detoxified by Glo1 (glyoxalase I), thereby preventing the accumulation of MG and MG-derived AGEs.
In the present review, data concerning MG, Glo1 and AGEs in the context of plaque phenotype are discussed.
Introduction
CVDs (cardiovascular diseases), such as heart attack and
stroke, are major causes of mortality worldwide [1]. The
disease underlying the vast majority of CVDs is atheroscler-
osis. An atherosclerotic plaque is formed by accumulation
of lipids and inflammatory cells between the medial and
intimal layers of arteries. Advanced atherosclerotic plaques
consist of a necrotic core containing cholesterol and dead
macrophages, flanked by macrophage-rich shoulder regions,
and are covered by a fibrous cap containing smooth muscle
cells and collagen. Stable plaques are characterized by more
collagen deposition, smooth muscle cells, fewer macrophages
and a small necrotic core [2]. Plaques at highest risk of rupture
are rich in macrophages and have a large necrotic core. In
addition, infiltration of leaky intraplaque vessels contribute
to intraplaque haemorrhages, increasing the risk of plaque
rupture [3]. Ruptured plaques are defined by a disruption of
the fibrous cap and a thrombus that is continuous with the
necrotic core, which may occlude an artery [3]. The risk of
plaque rupture is essentially a balance between inflammatory
activity and growth of the necrotic core against thickness
of the fibrous cap [4]. It is unknown why, in some plaques,
the fibrotic processes dominate, leading to stable plaques,
whereas in other plaques inflammation and necrosis take over,
leading to thinning of the fibrotic cap.
Previous studies have linked high metabolic activity in
atherosclerotic plaques [5] to the development of plaque
rupture. One feature of increased metabolic activity is
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formation of AGEs (advanced glycation end-products) [6].
Indeed, several studies have shown that AGEs accumulate in
human atherosclerotic plaques [7–10], and we found recently
that higher levels of AGEs in human carotid atherosclerotic
plaques are associated with a rupture-prone phenotype [11].
AGEs are a large family of extensively sugar-modified
proteins, but, rather than glucose itself, the dicarbonyl MG
(methylglyoxal) has been identified as the most reactive AGE
precursor [12]. MG has attracted a lot of attention as a key
player in vascular dysfunction, particularly due to its capacity
to induce the formation of oxidative stress, cell death and
endothelial dysfunction [12,13]. Therefore accumulation of
MG and MG-derived AGEs may be a major contributing
factor to plaque rupture. In the present review, we describe
various mechanisms of AGE formation, with a particular
focus on MG, and we discuss potential mechanisms for
how AGEs may contribute to atherosclerotic disease and how
lowering AGEs may have potential to treat CVD.
Formation of AGEs
It is thought that the formation of AGEs is an inevitable
consequence of (human) biology, associated with aging [14].
Increased metabolic activity, such as in diabetes, is associated
with increased AGE formation [15].
The Maillard reaction
Formation of AGEs was first described by Louis Camille
Maillard in 1912 [16]. The Maillard reaction is initiated by the
reaction of reducing sugars with protein residues, resulting
first in the formation of a Schiff base and subsequently, by
structural rearrangements, in Amadori products. Only a small
proportion of Amadori products are further, and irreversibly,
modified to AGEs. In the body, this entire reaction-chain
occurs slowly over a period of months. Therefore AGEs
derived from the Maillard reaction are mostly formed on
long-lived proteins, such as on collagen [14].
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Figure 1 Immunohistochemical staining of advanced carotid atherosclerotic lesions.
Images showing staining of CML (A) and MG-H1 (B) in the cytoplasm of macrophages (indicated by black arrows) surrounding
the necrotic core (indicated by the black line). In addition, CML (C) and MG-H1 (D) accumulate in plaque vessels (indicated
by white arrows). Images taken at ×200 magnification.
AGE formation via MG and the glyoxalase system
It is now well established that intermediates of glycolysis
are much more potent glycating agents than glucose
itself [17], suggesting that in vivo formation of AGEs
intracellularly is more abundant than AGE formation
via the slow Maillard reaction on connective tissues.
During glycolysis, highly reactive intermediates are formed,
including the dicarbonyl compound MG [12]. MG reacts
primarily with arginine residues to form the AGEs MG-
H1 [Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine or
5-hydro-5-methylimidazolone], argpyrimidine and THP
(tetrahydroimidazolone) as well as with lysine residues, to
form Nε-(carboxyethyl)lysine.
MG can be detoxified by Glo1 (glyoxalase I) and Glo2
(glyoxalase II) and reduced glutathione (GSH) into D-lactate
[18], thereby preventing accumulation of MG and MG-
derived AGEs. Overexpression of Glo1, the rate-limiting
enzyme in the glyoxalase system, has been shown to reduce
MG and AGEs in diabetes [15], and protects against vascular
dysfunction [19], retinopathy [20] and nephropathy [19] in
diabetic rats.
MG and AGE formation has mainly been studied in
the context of hyperglycaemia, although recent work has
demonstrated that inflammation and hypoxia are also major
determinants of MG formation [11]. For instance, both
hypoxia and inflammatory mediators such as TNFα (tumour
necrosis factor α) are associated with decreased Glo1 activity
in U937 monocytes, which may explain the concomitant
increase in MG found under these conditions [11].
AGEs in atherosclerosis
Several studies have described AGE accumulation in human
atherosclerotic plaques of the aorta [7], coronary artery [8],
carotid artery [9] and femoral artery [10], using antibodies
against glycated proteins [7–9] or the well-characterized AGE
CML [Nε-(carboxymethyl)lysine] [10,21,22]. Therefore ac-
cumulation of AGEs in atherosclerotic lesions seems to be
irrespective of the site of plaque development. Specific MG-
derived AGEs MG-H1 [11] and THP [23] have also been
detected in atherosclerotic plaques. Moreover, we found
recently that CML and MG-H1 levels in atherosclerotic
plaque, as measured in homogenates of plaques with
ultrahigh-performance liquid chromatography–MS/MS, are
associated with a rupture-prone phenotype [11], suggesting
that AGEs may contribute to events leading to plaque
rupture. Furthermore, in line with their high metabolic
activity, macrophages are the predominant cells in which
CML and MG-H1 accumulate in plaques, particularly
surrounding the necrotic core [11] (Figures 1A and 1B).
Additionally, staining of these AGEs was also found in plaque
vessels (Figures 1C and 1D).
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Factors contributing to AGE accumulation in
atherosclerosis
Several metabolic factors such as inflammation, hypoxia and
oxidative stress promote an increased accumulation of AGEs
in atherosclerotic plaques, whereas defensive mechanisms
against glycation may be decreased.
AGE formation via glycolysis
In human atherosclerotic plaques, [18F]fluorodeoxyglucose-
uptake experiments have shown that the macrophage is the
primary cell in which a high degree of glycolysis takes place
[5]. It has been demonstrated in cultured macrophages that
inflammation is a stronger trigger for glucose uptake than
hyperglycaemia [24]. The uptake of glucose under these
circumstances may contribute to increased formation of MG.
Indeed, we demonstrated recently that the cytokine TNFα
and hypoxia strongly increased MG and AGEs in monocytes
[11]. These findings are in accordance with strong associations
between plaque inflammatory markers and AGE levels, and
a striking co-localization between hypoxia and AGEs in
advanced atherosclerotic plaques in macrophages [11].
By contrast, hyperglycaemia leads to rapid accumulation
of AGE precursors, including MG in endothelium [17].
Furthermore, accumulation of AGEs in endothelial cells has
been linked with atherosclerotic lesion initiation in diabetes
[25].
Lipid-derived AGE accumulation
In addition to formation of AGEs from glucose and
glycolysis-derived precursors, AGEs can also be derived
from lipid peroxidation, of which the AGE CML is a well-
characterized example [26,45]. Since macrophages take up
large quantities of oxidized LDL (low-density lipoprotein) in
atherosclerotic lesions, AGEs derived from lipid peroxidation
in macrophages may also be of great physiological importance
in atherosclerosis. In addition, it has been demonstrated that
LDL itself is a target for MG. Modification of LDL by MG
decreases its particle size [27], increasing its atherogenicity,
and reduces its affinity for the LDL receptor [28], thereby
decreasing its clearance from the circulation and promoting
trapping of LDL in the vessel wall. Indeed, both CML
and MG-H1 levels are associated with lipid content of the
plaque [11], indicating that AGEs are (partly) derived from
lipid peroxidation and/or AGE-modified LDL particles in
atherosclerotic plaques.
Decreased Glo1 expression in ruptured plaques
Glo1 is abundantly present in the cytosol of virtually all
cells in the plaque (Figure 2). We demonstrated recently
that mRNA, protein and activity levels of Glo1 are lower
in ruptured plaques, which may leave cells in athero-
sclerotic plaques more susceptible to AGE accumulation.
Furthermore, previous experimental studies have shown
decreased Glo1 activity under conditions of metabolic stress,
such as hyperglycaemia [29], ischaemia [30], hypoxia and
inflammation [11]. Given the high metabolic activity in
Figure 2 Immunohistochemical staining of an advanced carotid
atherosclerotic lesion
Staining shows abundant staining of Glo1 in the cytoplasm of cells
throughout the plaque, except for the necrotic core (indicated by the
black line). Images taken at ×40 magnification.
atherosclerotic plaques, down-regulation of Glo1 may lead
to increased glycation in the plaque. Previous work has
shown that the promoter of Glo1 harbours an NF-κB
(nuclear factor κB)-responsive element [31], indicating a
link between inflammation and reduced Glo1 expression. In
addition, the Glo1 protein is susceptible to post-translational
modifications, in particular phosphorylation in response to
TNFα, a key mediator of inflammation [32]. Moreover, post-
translational modification of Glo1 by oxidized glutathione
(GSSG) and nitrosylation strongly inhibits Glo1 activity
[33,34]. The presence of such modifications on Glo1 in the
plaque remains unclear.
Glo1 is absent from the necrotic core of atherosclerotic
plaques (Figure 2). Therefore it is not conceivable that Glo1
offers full protection against extracellular AGE formation,
such as AGE formation from lipid oxidation of LDL particles.
Potential mechanisms for how MG and AGEs
contribute to plaque rupture
Two major mechanisms by which AGEs damage tissues
and contribute to the initiation, progression and rupture
of plaques can be proposed: first, intracellular glycation of
proteins, leading to impaired cell function, and secondly,
binding of AGEs to cellular receptors and subsequent
modulation of inflammatory gene expression.
Cytotoxicity of MG
Accumulation of MG in macrophages may contribute to
growth of the necrotic core of rupture-prone plaques, by
induction of apoptosis. This hypothesis is supported by the
fact that AGEs accumulate predominantly in the macro-
phages surrounding the necrotic core, co-localizing with
the apoptosis marker caspase 3 [11]. In vitro, MG induces
apoptosis of macrophages in an oxidative-stress-dependent
mechanism [35].
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Furthermore, AGE-positive plaque vessels also stain for
caspase 3 [11]. Therefore accumulation of MG and AGEs
in plaque vessels may contribute to their dysfunction
and leakage, further exacerbating their risk of intraplaque
haemorrhage and subsequent plaque rupture. Accordingly,
MG impairs proteasome function in endothelial cells [36],
and indeed induces apoptosis [37]. Interestingly, AGEs have
been shown to promote angiogenesis [38,39], which suggest
that accumulation of AGEs in plaques may not only influence
the function, but also the amount of plaque vessels. This may
be of pathophysiological relevance, as a higher amount of
plaque microvessels is strongly associated with a rupture-
prone plaque phenotype [3].
Furthermore, it has been demonstrated that intracellular
accumulation of MG in endothelial cells causes dysfunction
as indicated by expression of adhesion molecules such as
VCAM-1 (vascular cell adhesion molecule 1) expression,
which can be prevented by Glo1 overexpression [40]. There-
fore AGE accumulation in endothelial cells may contribute
to atherosclerotic plaque formation by attracting more
monocytes to the plaque. Interestingly, El-Osta et al. [41]
demonstrated elevated MCP1 (monocyte chemoattractant
protein 1) expression and concomitant adverse epigenetic
changes in endothelial cells of even normoglycaemic Glo1-
knockdown mice [41], suggesting that exposure to MG leads
to a prolonged risk of atherosclerosis.
Inflammation through interaction with RAGE
RAGE (receptor for AGEs) links the accumulation of AGEs
to inflammatory pathways associated with atherosclerosis.
Activation of RAGE leads to activation of NF-κB [42] and
downstream inflammatory signalling. Furthermore, genetic
deletion of RAGE greatly reduces atherosclerosis in Apoe− / −
(apolipoprotein E-knockout) mice [43]. In addition, admin-
istration of soluble RAGE reduced atherosclerosis in STZ
(streptozotocin)-injected diabetic Apoe− / − mice. Moreover,
in human plaques, RAGE co-localizes with MMP-9 (matrix
metalloproteinase 9), a major collagen-digesting enzyme, and
RAGE signalling is implicated in weakening of the fibrous cap
of the plaque [44]. CML, which is present in high amounts
in atherosclerosis and is considered an important ligand
for RAGE [45] is associated with MMP-9, as well as IL-8
(interleukin 8) and MCP1 in plaques [11]. However, many
inflammatory cytokines, such as S100b and HMGB1 (high-
motility group box 1) [46] are ligands for RAGE, and which
of these ligands is the major ligand for RAGE in the plaque is
not clear. Interestingly, an interplay between RAGE and the
glyoxalase system has been described, as Glo1 overexpression
prevents RAGE up-regulation [47].
Targeting AGEs for CVD therapy
Evidence for a causal role for AGEs in atherosclerosis is
obtained primarily by the use of AGE inhibiting compounds
in Apoe− / − mice.
The best characterized inhibitor of AGE formation is
aminoguanidine [48]. Administration of this compound
reduced plaque formation in STZ-induced diabetic Apoe− / −
mice [49]. In addition to AGE- and MG-lowering properties,
aminoguanidine has been described as an antioxidant [50]
and inhibitor of nitric oxide formation [51]. Likewise,
pyridoxamine (vitamin B6) is considered an AGE inhibitor,
with antioxidant and anti-inflammatory properties [52], that
can reduce atherosclerosis in STZ-induced diabetic Apoe− / −
mice [53].
Alagebrium is a compound capable of breaking pre-
existing AGE cross-links that has also been shown to lower
MG levels directly [54]. Alagebrium has been shown to reduce
atherosclerosis in STZ-induced diabetic Apoe− / − mice,
although it is unclear whether or not this beneficial effect
was attributable to its AGE- or MG-lowering properties [49].
Despite these animal studies, it is currently unknown whether
these compounds indeed reduce cardiovascular events in
humans [55], as mice do not spontaneously develop plaque
rupture. Interestingly, established drugs to treat CVD, such as
simvastatin, have also been shown to reduce the accumulation
of AGEs in human carotid plaques [9]. Similarly, several
glucose-lowering [56] and antihypertensive compounds [57]
have been shown to have AGE-lowering properties. Whether
beneficial effects of these drugs are partly attributable to
AGE lowering, or whether the AGE-lowering effects of these
compounds merely reflect their anti-inflammatory, glucose
lowering or other actions remains to be determined.
Conclusion
AGEs are higher in rupture-prone plaques and may
contribute to the increased risk of plaque rupture. This may be
aggravated further by an impaired defence against glycation
by a down-regulation of Glo1 and, as a consequence,
increased formation of MG. Cytotoxicity and induction of
inflammation are potential downstream effects of MG and
AGE accumulation. A simplified overview of how this axis
may link inflammation to the development of plaque rupture
is given in Figure 3.
Many unresolved questions remain regarding precise
mechanisms and the extent to which MG and AGEs
contribute to progression of atherosclerosis. Importantly,
interventions that specifically reduce AGEs without inter-
vening in other athero-reducing mechanisms are still lacking,
and it has not been shown that AGE interventions in
humans reduce cardiovascular risk. Intervention studies,
preferably with more specific inhibitors of MG and/or AGEs,
are needed to determine further the extent to which MG
and AGEs play a causal role in human atherosclerosis.
In addition, interruption of RAGE signalling may prove
successful in treating human atherosclerotic disease, as it is
in mice. Furthermore, increasing Glo1 expression and/or
activity may prove valuable to reduce cardiovascular risk.
For example, beneficial effects of the angiotensin receptor
blocker candesartan on retinopathy have been attributed
to its Glo1-restoring capacities [58]. Furthermore, AGEs
measured in the circulation may serve as biomarkers of CVD
risk. Unfortunately, little research has focused on which
specific circulating AGEs best reflect AGE accumulation
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Figure 3 Simplified overview of how MG and AGEs may link plaque inflammation and development of plaque rupture.
in atherosclerotic lesions. The value of specific AGEs for
risk prediction for CVD should be determined in large
prospective cohort studies.
Taken together, AGEs, MG and Glo1 may contribute
to the increased risk of plaque rupture in inflammatory
and metabolically active plaques. Developing therapeutic
interventions directed at reducing AGE levels, restoring Glo1
activity and/or interrupting in the RAGE axis is a major
challenge to combat the development of CVD.
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